作者: Rebecca L Roberts , Murray L Barclay
DOI: 10.1111/J.1440-1746.2012.07220.X
关键词:
摘要: No drug therapy is completely risk free, and the costs associated with non-response adverse effects can exceed cost of therapy. The ultimate goal pharmacogenetic research to find robust genetic predictors response that enable development prospective tests reliably identify patients at or developing an effect prior being prescribed. Currently, thiopurine S-methyltransferase (TPMT) deficiency only factor prospectively assessed before azathioprine 6-mercaptopurine immunomodulation commenced in Crohn's disease (CD). As yet no other inherited determinant has made transition from bench bedside for management this disease. In review we summarize what known about TPMT explore whether there evidence support a role polymorphisms predicting CD drugs, methotrexate, anti-tumor necrosis α (TNFα)